In the United States, through the Biological Safety Law proposal and restrict the business exchanges of some Chinese pharmaceutical companies on the grounds of national security, Wuxi Pharmaceutical Kant in China will issue a zero interest rate of 500 million US dollars (about S $ 650 million).Convertible bonds.
Comprehensive Reuters and Hong Kong Radio reported on Tuesday (October 8) reported that the above bonds issued by Wuxi Medicine Kant expired in 2025, and the preliminary conversion price of bonds was HK $ 80.02 per share (about 13.42 per share (about 13.42Singapore), nearly 16%compared with Monday (October 7).If the number of conversion bonds is converted to 48.522 million H shares, which is equivalent to 11.14%of the total H -shares issued by the expanded.
Wuxi Medicine Kangde's expected net amount is US $ 494 million, and funds will be used for global business development, debt reinstatement and general company use.
In addition, Wuxi Yaoming Kant said on Tuesday that the company is currently evaluating various options to maintain the continuous operation of the Wuxi ATU business and does not sign any binding substantial agreement with any relevant party.
Wuxi Yaoming Kangde said that during the assessment process, the first consideration was the Wuxi ATU employees and all the treatment plans that urgently needed Wuxi ATU provided to save life.
The U.S. House of Representatives passed the Biological Safety Law proposal on September 9th, which aims to restrict the business exchanges with biotechnology companies such as China Pharmaceutical Kangde and Huada Gene on the grounds of national security.After passing this proposal, the House of Representatives has been submitted to the Senate and must be passed in the Senate before being sent to President Biden to sign a law.
E -Kangde, which is included in the blacklist by the United States, has never collected human genome data, nor does it constitute a national security risk to any country.
